Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 17/20 | 0.54 |
| ▸ | CDK4 | P11802 | 3/20 | 0.37 |
| ▸ | CCND1 | P24385 | 3/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.36 |
| ▸ | PRKACA | P17612 | 2/20 | 0.36 |
| ▸ | PRKACG | P22612 | 2/20 | 0.36 |
| ▸ | PRKACB | P22694 | 2/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7860461 | 0.92 | TOP1 (0.54) | TOP1CDK4CCND1CCNE2PRKACA | |
| SCHEMBL7861913 | 0.89 | TOP1 (0.65) | TOP1 | |
| SCHEMBL5870061 | 0.88 | TOP1 (0.58) | TOP1CDK4CCND1CCNE2PRKACA | |
| SCHEMBL5870245 | 0.88 | TOP1 (0.51) | TOP1CDK4CCND1CCNE2PRKACA | |
| SCHEMBL5870514 | 0.84 | TOP1 (0.61) | TOP1 | |
| SCHEMBL6724824 | 0.84 | TOP1 (0.61) | TOP1 | |
| SCHEMBL5869927 | 0.82 | TOP1 (0.55) | TOP1CDK4CCND1CCNE2PRKACA | |
| SCHEMBL6736290 | 0.82 | TOP1 (0.57) | TOP1CDK4CCND1CCNE2PRKACA | |
| SCHEMBL8192076 | 0.82 | TOP1 (0.52) | TOP1CDK4CCND1CCNE2PRKACA | |
| SCHEMBL5870241 | 0.82 | TOP1 (0.51) | TOP1CDK4CCND1CCNE2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138377-B2 | Topoisomerase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-6653290-B2 | Sugar derivatives of indolocarbazoles; exhibit topoisomerase-I activity | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-25 | — | — | US | disclosed |
| US-20030203860-A1 | Substituted sugar derivatives of indolopyrrolocarbazoles, useful in inhibiting the proliferatin of tumor cells | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-30 | — | — | US | disclosed |
| US-20020068705-A1 | Tumor proliferation inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068705-A1 | Tumor proliferation inhibitors | MKI67, TOP1, CCNI | TOP1 2/4885CDK4 19/4885CCND1 27/4885 |
| US-20030203860-A1 | Substituted sugar derivatives of indolopyrrolocarbazoles, useful in inhibiting the proliferatin of tumor cells | TYMP, MKI67, CCNI | TOP1 5/4885CDK4 7/4885CCND1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.